Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies. 


    Thanks for your interest, you'll find the intake form here. 

     Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

    We will not share or sell this info with any third party.

  • Connect With Prism Research on Social Media

    You can WIN TICKETS VIA Prism's Facebook page!

    Have you LIKED Prism Clinical Research on Facebook?

    Have you TAGGED Prism Clinical Research on Twitter?

    Have you FOLLOWED Prism Clinical Research on Instagram?

     

    Use the link below:↓

    https://www.facebook.com/PrismResearch/

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Let's Talk About Endometriosis

    Prism Research has upcoming studies for individuals diagnosed with moderate to severe Endometriosis.  These studies will help determine how an investigational drug is broken down and removed from the body.

     If you or someone you know has been diagnosed with endometriosis and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $225-$2600.

    Let's Talk 

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

     

     

  • Diagnosed with Celiac Disease?

    Prism Research has upcoming studies for individuals who have been diagnosed with Celiac Disease.  These FDA approved studies will help determine how an investigational drug being developed for Celiac Disease is broken down and removed from the body in volunteers diagnosed with Celiac Disease.

    If you or someone you know has been diagnosed with Celiac Disease and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Participants who qualify will receive a no cost health evaluation in addition to financial compensation for study participation time.

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com for more information on these upcoming studies for individuals diagnosed with Celiac Disease.

    Upcoming Study: 1803

    Cour Pharmeceuticals New Drug

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

    Upcoming Study: 1801

  • Diagnosed with Kidney Impairment?

    Prism Research has upcoming studies for individuals diagnosed with kidney impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of kidney impairment when compared to volunteers with normal kidney function.

     If you or someone you know has been diagnosed with kidney impairment and are interested in being considered for these studies, please contact Lindsay at 651-368-3360 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Please contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

  • Study 1708: Male and Female Participants with Migraine

    Research Purpose: Study 1708 is designed to evaluate the cognitive effects in participants receiving topiramate for prophylactic treatment of migraine comparing immediate release versus extended release formulations. Participants will receive dosings of both FDA approved formulations of topiramate.

     The following will be evaluated:

    • The effect of multiple doses of topiramate (immediate release and extended release) on cognition in participants with migraine.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Women using acceptable forms of birth control are allowed to participate.

    Age

    18-65 years

    Body Mass Index (BMI)

    There is no body mass index requirement for this study.

    Weight

    There is no weight requirement for this study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Health History

    History of episodic migraine with or without aura for at least 6 months prior to the screening visit and a frequency of 3 or more headache attacks per month during the past 3 months.

    Right hand dominant.

    On a stable dose for 3 months of a selective serotonin reuptake inhibitor for depression and/or anxiety.

    Special Requirements
    • Must be able and willing to take oral doses of the study medication at home.
    • Must have a working phone number during the entire study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay
    • Participants will admit to Prism Clinical Research 3 times
    • The inpatient stay is approximately 1 day one time (1 overnight) and 2 days two times  (2 overnights)

    Outpatient Visits
    • There are 3 outpatient visits during the study.
    • The outpatient visits are approximately 2 hours long. 

     

    Compensation for participation time:   Up to $­­­­­­­­­­­­­­1,660.00

    First screen: 8/28

    First Admit; 9/11

    For information regarding this study contact Kevin at 651-724-5046

  • Healthy Male and Female: Clinical Research Study 1720

    Research Purpose:

    To evaluate the safety, tolerability and absorption rate of an investigational drug being developed for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Men and women must agree to practice a highly effective method of contraception during the course of the study.

    Age

    18-55 years

    Weight/Body Mass Index (BMI)

    Weight greater than 121 and less than 187 lbs and

    BMI between 18.5-30 kg/m²

    Tobacco/Nicotine Use

    Use of tobacco or tobacco containing products is not permitted. 

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Medications

    No use of dietary supplements, vitamins, herbal medications, non-prescription medications or prescription medications (other than hormonal birth control) from seven days before study admission through the end of the study.

     

    Study Time Commitment:

    For participants who qualify based on screening evaluation, study participation will last for approximately 40 Days.

    Clinic Stay
    • Participants will admit to Prism Clinical Research one (1) time.
    • The in-clinic stay will last approximately 12 days, (11 overnights).

    Outpatient Visits
    • There are no return clinic visits.

     

     

    Compensation for participation time:

    Up to $2,875.00

     

    For information regarding this study contact:

     Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

    Dayna at 651-724-5047 or daynas@prismresearchinc.com

     

  • Liver Impairment: Clinical Research Study 1801

    LIVER IMPAIRMENT STUDY

    CLINICAL RESEARCH STUDY: 1801

     

    PRISM CLINICAL RESEARCH

     

     

    PURPOSE:

    To determine how the investigational drug is absorbed, broken down, and removed from the body in volunteers with liver impairment compared to volunteers with normal liver function.

     

    GENERAL STUDY REQUIREMENTS:

    Men and Women Between the ages of 18 and 70 years old

    Liver Impairment volunteers: must have mild/moderate liver impairment due to diagnosed liver disease.

    Healthy volunteers: must be healthy; not being evaluated or treated for any medical conditions.

     

    STUDY DURATION:

    1 In-Clinic Stay: Lasting 4 nights/ 5 days

    1 Follow Up Phone Call

    Total Study Duration is Approximately 2 Months

     

    METHOD OF ADMINISTRATION:

    Oral Administration

     

    STUDY COMPENSATION:

    Compensation for Study Participation may be provided for time and travel up to $1,310

     

    RECRUITMENT CONTACT:

    Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Kidney Impairment: Clinical Research Study 1802

    RENAL IMPAIRMENT STUDY

    CLINICAL RESEARCH STUDY: 1802

     

    PRISM CLINICAL RESEARCH

     

    PURPOSE:

     To evaluate the safety and tolerability of an investigational drug in

    individuals with renal impairment compared with individuals without renal

    impairment. This study is for research purposes only and is not intended to

    treat your kidney disease.

     

    GENERAL STUDY REQUIREMENTS:

     Men and Women over the age of 18 and with a Body Mass Index (BMI) of

    less than 45kg/m2.

     Medical conditions must be stable in the opinion of the study doctor.

    Volunteers with diabetes mellitus would not qualify.

     

    STUDY DURATION:

     In Clinic Stay: 7 nights/8 days.

     Return Clinic Visits: 2, including screening.

    Total study duration is approximately 6 weeks (including a 28-day screening

    period).

     

    METHOD OF ADMINISTRATION:

     Oral Administration

     

    STUDY COMPENSATION:

     Compensation for Study Participation Time Up To: $2,375.00

     

    RECRUITMENT CONTACT:

     Lindsay 651-368-3360 or lindsayd@prismresearchinc.com

     

  • Study 1803 (Part A): Healthy Males and Females with Celiac Disease

    Research Purpose: To evaluate an investigational drug being developed for the treatment of Celiac Disease.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate and must agree to use an acceptable form of birth control

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women using an acceptable method of birth control are allowed to participate.

    Age

    18-75 years of age

    Weight/Body Mass Index (BMI)

    BMI between 18-25 kg/m² and weight between 72-284lbs

    Health History
    • Diagnosed by biopsy with Celiac Disease
    • Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.
    • No known gluten exposure for at least 10 days prior to screening visit

    Medications

    All medications will be approved on a case by case basis.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 6 months, not including screening.

    Schedule

    Clinic Stay
    • Participants will admit to Prism Clinical Research 1 time.
    • The in-clinic stay will last approximately 4 days (3 overnights).

    Return Clinic Visits
    • There are 4 clinic visits
    • There are 7 phone call visits

    Compensation for participation time up to: $1,700

     

    For information regarding this study contact Dayna 651-724-5047 daynas@prismresearchinc.com 

  • Asthma: Clinical Research Study 1804

    PURPOSE:

    * To evaluate the safety and tolerability of an investigational drug in individuals diagnosed with persistent asthma who are being treated and are on a stable asthma therapy.

     

    GENERAL STUDY REQUIREMENTS:

    *Men and Women Between The age of 18 and 65

    * Individuals with Asthma on a stable Asthma Therapy

     

    STUDY DURATION:

    * 3 In-Clinic Stays: Each Lasting 4 nights/5 days

    * Return Clinic Visits: 10, Including Screening

    * Total Study Duration is Approximately 35 Weeks

     

    METHOD OF ADMINISTRATION:

    * Subcutaneous Dosing

     

    STUDY COMPENSATION:

    * Compensation for Study Participation may be granted for time and travel

     

    RECRUITMENTCONTACT:

    *  Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1710 (Part 2): Individuals with Moderate Renal Impairment

    Research Purpose: To determine whether the investigational drug displays the clinical safety profile to support further development in patients with moderately impaired renal function.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential are allowed to participate

    Age

    40-85 years of age

    Body Mass Index (BMI)

    Between 18-40 kg/m²

    Minimum Weight

    50 kg

    MDRD

    30-59 mL/min/1.73 m²

    Angiotensin receptor blocker (ARB)

    Must be on an ARB for at least one month prior to screening

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 13 weeks. 

    Clinic Stay
    • Individuals participating in the inpatient portion of the study will be confined at Prism Clinical Research one time during the study period for 8 days and (7 nights)

    Return Clinic Visits
    • Individuals participating in the inpatient portion of the study will return to the clinic for 4 outpatient visits (not including screening) and 1 telephone follow up call.
    • Individuals participating in the outpatient portion of this study will have 7 outpatient clinic visits (not including screening) and 1 telephone follow up call.

     

    Screenings begin:10/23/2017

    Anticipated start date for Study 1710 (Part 2): 6Nov2017

    Compensation for participation time:

    • If you participate is in the inpatient portion of the study, up to $2800.00 upon completion of all clinic visits and follow-up phone call.
    • If your participation does not require you to participate in the inpatient portion of the study, up to $1075.00 upon completion of all clinic visits and follow-up phone call.

     

     

    For information regarding this study contact Kevin at: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

     

  • Kidney Impairment: Clinical Research Study 1807

    RENAL IMPAIRMENT STUDY

    CLINICAL RESEARCH STUDY: 1807

    PRISM CLINICAL RESEARCH

     

    PURPOSE:

     To evaluate the safety and tolerability of an investigational drug in individuals with renal impairment compared with individuals without renal impairment.

     

    GENERAL STUDY REQUIREMENTS:

     Men and non-child bearing potential Women, between the ages of 18 to 75 with a Body Mass Index (BMI) between 17.5 and 40 kg/m2.

     Medical conditions and medications must be stable in the opinion of the study doctor.

     

    STUDY DURATION:

     In Clinic Stay: 6 nights/7 days.

     Return Clinic Visits: 2-3, including screening.

     Total study duration is approximately 2 months (including a 28-day screening period).

     

    METHOD OF ADMINISTRATION:

     Oral Administration

     

    STUDY COMPENSATION:

     Compensation for Study Participation Time Up To: $2,385.00

     

    RECRUITMENT CONTACT:

     Lindsay 651-368-3360 or lindsayd@prismresearchinc.com

     

  • Dialysis: Clinical Research Study 1809

    Study for Hemodialysis Patients

    Clinical RESEARCH study: 1809 (DS2330-A-U103)

     

    PRISM clinical RESEARCH

     

    Purpose:

    •  To evaluate the safety and tolerability of an investigational drug in individuals on hemodialysis and in combination with a known FDA approved medication, sevelamer.

     

    GENERAL STUDY REQUIREMENTS:

    •  Men and Women between the age of 18 and 80 with a body mass index (BMI) between 18kg/m²and 40kg/m².
    •  Volunteers must be on hemodialysis for the past 3 months

     

    STUDY DURATION:

    •  In Clinic Stay: 15 nights/16 days.
    •  Return Clinic Visits:  Up to 8, including screening.
    •  Total study duration is approximately 10.5 weeks (including a 29 day screening period).

     

    METHOD OF ADMINISTRATION:

     Oral Administration

     

    STUDY COMPENSATION:

    •  Compensation for Study Participation Time Up To: $5,195.00

     

    RECRUITMENT CONTACT:

     

     

     

     

  • Upcoming Studies

     

     

     Prism has a variety of upcoming studies to participate in: 

    • Studies for healthy males and females 
    • Liver Impairment (Study 1801)
    • Kidney Impairment 
    • Endometriosis- Associated Pain

    To be put on the call list and receive more information, when available, please contact Dayna at daynas@prismresearchinc.com or Lindsay at lindsayd@prismresearchinc.com.

Getting to Prism

Prism Clinical Research is located in University Enterprise Laboratories.

1000 Westgate Drive, Suite 149, St. Paul, MN 55114 

When you arrive: 
All outdoor signs read UEL. Parking is Free.
 Enter the main door under UEL awning. 
Turn right as soon as you enter the lobby.
 Prism will be on your right, suite 149.


Prism is conveniently located just two blocks north of the Westgate stop on the Metro Transit Green Line. For complete schedule and route information visit the Metro Transit site.

Click on the map below or see the written directions below to find us.

(Please be advised road construction on HWY 280 will affect your route to Prism)


View Larger Map

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel